Biocon Limited — Updates, 15-04-2025: Press Release

Biocon Biologics has secured a settlement and license agreement with Regeneron, allowing it to commercialize Yesafili™, an interchangeable biosimilar to Eylea®, in the U.S. This agreement paves the way for a market entry as early as the second half of 2026. Yesafili™ is intended for treating multiple ophthalmic conditions and has demonstrated comparable quality, safety, and efficacy to the reference product Eylea®. In Canada, Biocon Biologics has also reached a settlement for a launch by July 1, 2025. With this entry into ophthalmology, Biocon aims to enhance patient access to this critical therapeutic solution, bolstering its growth strategy and expanding its presence in the U.S. market. Investors should monitor this positive development as it could significantly impact Biocon’s market positioning and revenue streams in the coming years.